scTrends: A living review of commercial single-cell and spatial 'omic technologies.

Autor:	De Jonghe J; Francis Crick Institute, London, UK., Opzoomer JW; Cell Communication Lab, Department of Oncology, University College London Cancer Institute, London, UK; Relation Therapeutics, London, UK., Vilas-Zornoza A; Relation Therapeutics, London, UK., Nilges BS; OMAPiX GmbH, Langenfeld, Rheinland, Germany., Crane P; Caeruleus Genomics, Oxford, UK., Vicari M; Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Sweden., Lee H; spatialist AB, Stockholm, Sweden; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 171 65 Solna, Sweden., Lara-Astiaso D; Department of Hematology, University of Cambridge, Cambridge, UK; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK., Gross T; Relation Therapeutics, London, UK., Morf J; Skyhawk Therapeutics, Basel, Switzerland., Schneider K; Roche, Basel, Switzerland., Cudini J; Relation Therapeutics, London, UK., Ramos-Mucci L; Relation Therapeutics, London, UK., Mooijman D; Single Cell Discoveries, Utrecht, the Netherlands., Tiklová K; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 171 65 Solna, Sweden., Salas SM; spatialist AB, Stockholm, Sweden; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 171 65 Solna, Sweden., Langseth CM; spatialist AB, Stockholm, Sweden; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 171 65 Solna, Sweden., Kashikar ND; OMAPiX GmbH, Langenfeld, Rheinland, Germany., Schapiro D; Institute for Computational Biomedicine, Heidelberg University, Faculty of Medicine, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Spatial Profiling Center (TSPC), Heidelberg, Germany., Lundeberg J; Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Sweden., Nilsson M; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 171 65 Solna, Sweden., Shalek AK; Relation Therapeutics, London, UK; Institute for Medical Engineering and Science, Department of Chemistry and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Cribbs AP; Caeruleus Genomics, Oxford, UK; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute of Health Research Oxford Biomedical Research Unit (BRU), University of Oxford, Oxford, UK; Oxford Centre for Translational Myeloma Research University of Oxford, Oxford, UK. Electronic address: adam.cribbs@ndorms.ox.ac.uk., Taylor-King JP; Relation Therapeutics, London, UK. Electronic address: jake@relationrx.com.
Jazyk:	angličtina
Zdroj:	Cell genomics [Cell Genom] 2024 Dec 11; Vol. 4 (12), pp. 100723.
DOI:	10.1016/j.xgen.2024.100723
Abstrakt:	Understanding the rapidly evolving landscape of single-cell and spatial omic technologies is crucial for advancing biomedical research and drug development. We provide a living review of both mature and emerging commercial platforms, highlighting key methodologies and trends shaping the field. This review spans from foundational single-cell technologies such as microfluidics and plate-based methods to newer approaches like combinatorial indexing; on the spatial side, we consider next-generation sequencing and imaging-based spatial transcriptomics. Finally, we highlight emerging methodologies that may fundamentally expand the scope for data generation within pharmaceutical research, creating opportunities to discover and validate novel drug mechanisms. Overall, this review serves as a critical resource for navigating the commercialization and application of single-cell and spatial omic technologies in pharmaceutical and academic research. Competing Interests: Declaration of interests J.D.J., J.W.O., and A.P.C. are inventors on patent applications filed by the University of Cambridge (via Cambridge Enterprise), the University College London Business, and Oxford University Innovations, respectively. J.W.O., A.V.Z., T.G., J.C., L.R.-M., C.E.S.R., A.K.S., and J.P.T.-K. receive compensation from Relation Therapeutics. P.C. and A.P.C. are employees of Caereleus Genomics. B.S.N. and N.D.K. receive compensation from OMAPiX. M.V. and J.L. are scientific consultants for 10× Genomics. J.M. receives compensation from Skyhawk Therapeutics and previously worked as a scientific consultant for Scipio Bioscience. K.S. receives compensation from Roche. D.M. receives compensation from scDiscoveries. H.L., S.M.S., and C.M.L. receive compensation from spatialist. A.K.S. reports compensation for consulting and/or scientific advisory board membership from Honeycomb Biotechnologies, Cellarity, Ochre Bio, Relation Therapeutics, Bio-Rad Laboratories, IntrECate Biotherapeutics, Passkey Therapeutics, Fog Pharma, and Dahlia Biosciences, which are unrelated to this work. D.S. reports funding from Cellzome, a GSK company, and received honorariums from Immunai, Noetik, Alpenglow, and Lunaphore. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu